Twi Pharmaceuticals Inc., of Taipei, Taiwan, said its subsidiary, Twi Biotechnology Inc., and Castle Creek Pharmaceuticals LLC, a spin-off of Northbrook, Ill.,-based Marathon Pharmaceuticals LLC, entered a development and commercialization agreement for Twi's lead drug candidate, AC-203, in development for the treatment of epidermolysis bullosa.